← Al het nieuws

$225 million for uniQure

uniQure, a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs today announced the pricing of its underwritten public offering of 4,891,305 of its ordinary shares at a public offering price of $46.00 per share. The gross proceeds to uniQure from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses payable by uniQure, are expected to be approximately $225 million. All ordinary shares to be sold in the offering are being sold by uniQure. In addition, uniQure has granted to the underwriters a 30-day option to purchase up to 733,695 additional ordinary shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about September 10, 2019, subject to the satisfaction of customary closing conditions.

Source: uniQure